NSG BioLabs bags US$14.5 million funding; inks tie-ups with Merck, EnterpriseSG
The funds will go towards new facilities and co-working sites, likely around the Biopolis and one-north area
Add BT as a preferred source
BIOTECH co-working provider NSG BioLabs secured a US$14.5 million funding round led by private equity player Celadon Partners, it announced on Tuesday (May 7). Temasek-backed biotech investor ClavystBio also joined in the round.
The funds will be used to establish more facilities and co-working laboratory sites. Currently, NSG BioLabs has three Biosafety Level 2 laboratory and office sites, which allow for work with chemicals and agents with moderate potential hazard to personnel and the environment.
“We are looking to expand to more sites in Singapore,” Daphne Teo, chief executive and founder of NSG BioLabs, told The Business Times.
TRENDING NOW
Shanda co-founder sells Tanglin Hill bungalow for S$76 million
Jumbo Seafood to close flagship East Coast Seafood Centre outlet on Sep 30
Nearly half of Apac’s wealthy expect market crash or correction, plan to rotate to cash: study
Trek 2000 shares jump 41.5% after Osim founder Ron Sim drops claims, sells 7.3% stake to Azure Capital
